Stock Analysis, Dividends, Split History

DPUKY / Dominos Pizza UK and IRL Plc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.79
Volume135,900.00
Market Cap ($M)326.15
Enterprise Value ($M)3,605.32
Book Value ($M)-2,929.20
Book Value / Share-69.95
Price / Book-0.11
NCAV ($M)682.91
NCAV / Share16.31
Price / NCAV0.48
Share Statistics
Common Shares Outstanding 43,018,242
Common Stock Shares Outstanding 42,898,329
Scoring Models
Piotroski F-Score8.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.66
Return on Assets (ROA)0.39
Return on Equity (ROE)-0.15
Balance Sheet (mrq) ($M)
Assets954.57
Liabilities0.00
Quick Ratio1.70
Current Ratio1.81
Income Statement (mra) ($M)
Domestic Supply Chain Revenues0.00
Domestic Company Owned Stores Revenues0.00
Revenues2,787,979,000.00
Revenue Reduction Due To Profit Sharing Arrangements119,700,000.00
International Revenues0.00
Franchise Revenue0.00
Operating Income521.23
Net Income277.90
Earnings Per Share Basic6.05
Earnings Per Share Diluted5.83
Cash Flow Statement (mra) ($M)
Cash From Operations339.04
Cash from Investing-149.00
Cash from Financing339.04
Identifiers and Descriptors
CUSIP25754W104
Central Index Key (CIK)1286681

Split History

Stock splits are used by Dominos Pizza UK and IRL Plc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

When sorry isn't enough — pressure grows on companies to apologize quickly in the age of viral content

2018-08-22 cbc.ca
Smartphones, social media, and the speed at which videos go viral are creating new pressures in boardrooms everywhere, whenever executives have to quickly handle a mess-up.

UPDATE 1-Britain's FTSE dips as lira crisis continues, esure surges

2018-08-13 reuters
LONDON, Aug 13 (Reuters) - British shares dipped on Monday as the Turkish currency crisis continued to rattle global markets while a possible 1.17 billion pound bid for esure sent shares in the insurance company surging over 30 percent.

Britain's FTSE dips as lira crisis shakes world markets

2018-08-13 reuters
LONDON, Aug 13 (Reuters) - British shares dipped on Monday as the Turkish currency crisis continued to shake global markets with stock indexes declining from Asia to Europe.

Chipotle: Wait To Buy Until New CEO Shows Results

2018-07-09 seekingalpha
New CEO Brian Niccol has promised investors sales will double in the foreseeable future, which has set high expectations for Chipotle's future performance.

News Live: RBI failed to conduct proper auditing, says CVC on PNB fraud

2018-04-03 moneycontrol
Air cargo volumes are expected to grow 60% over the next five years, but the infrastructure bottlenecks are a major constraint which can impede the sector's ability, rating agency Icra said in a report. It also called for an increase in the cargo handling capacity by nearly 50% to support demand. (13-0)

CUSIP: 25754W104